All In Biotech

Drug Trial Radar · NCT05751850

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate Versus Nab-paclitaxel in Combination With Gemcitabine for First-line Treatment of Advanced Pancreatic Cancer: an Open, Randomized, Multicenter Phase III Trial.

Last checked: Nov 19, 2026Latest source record: May 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 778 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

778

Planned (sponsor's estimate)

Start

Jun 13, 2023

Primary completion

Dec 30, 2024

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

Conditions

  • First-line Treatment of Advanced Pancreatic Cancer

Interventions

  • HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinateDrug

    HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate

  • nab-paclitaxel; gemcitabineDrug

    nab-paclitaxel in combination with gemcitabine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: From study start until 399 OS events have occurred (approximately 15 months after last patient enrollment)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.